Objective To explore the expressions of androgen （AR） and Stathmin in triple negative breast cancer （TNBC） and analyze the correlation between these expressions and clinicopathologic features. Methods Eighty-three patients who were diagnosed as TNBC and met the inclusion criteria from 2005 to 2009 in the Sichuan Provincial People’s Hospital were collected retrospectively. The expressions of AR and Stathmin in the TNBC tissues by using the method of EnVision immunohistochemistry. The correlation between AR or Stathmin expression and age， tumor size， lymph node status， or histological grade was analyzed by Spearman test. Results The AR and Stathmin positive expression rates in the patients with TNBC were 37.3% （31/83） and 98.8% （82/83）， respectively. The AR expression was positively correlated with age（rs=0.302， P=0.006）and pathological grade （rs=0.225， P=0.041）， but was not correlated with tumor size or lymph node status. The Stathmin expression was not correlated with age， tumor size， lymph node status， or pathological grade （P＞0.05） . Conclusions The AR expression is correlated with the age or pathological grade but Stathmin expression was all not correlated with the clinicopathologic features. AR or Stathmin as a prognosis indicator in patients with TNBC are needed to more research.
ObjectiveTo investigate the correlation between the expressions of matrix metalloproteinase-3 (MMP-3) and vascular endothelial growth factor (VEGF) in the three negative breast cancer (TNBC) and analyze their clinicopathologic significances. MethodsOne hundred and twelve patients confirmed TNBC from January 2008 to January 2013 in this hospital were collected. The cases of luminal type with the similar pathological type and pathological staging were chosen as control. The expressions of MMP-3 and VEGF were detected by immunohistochemistry. Results①The positive expression rates of MMP-3 and VEGF in the TNBC tissues were significantly higher than those in the luminal tissues[MMP-3:90.18%(101/112) versus 49.11%(55/112), P < 0.05;VEGF:84.82%(95/112) versus 48.21%(54/112), P < 0.05]. 2 The positive expressions of MMP-3 and VEGF in the TNBC tissues were correlated with age, menopausal status, tumor size, axillary lymph node metastasis, and TNM stage(P < 0.05).③The expression of MMP-3 was positively correlated with VEGF in the TNBC tissues(rs=0.711, P < 0.01).④The results of follow-up showed that the recurrence and metastasis rate within 3 years was 73.21%, the survival rate within 5 years was 36.61% in the patients with TNBC. ConclusionsThere is a close relation between MMP-3 and VEGF in TNBC, the expressions of MMP-3 and VEGF may serve as important biomarkers for evaluating invasion and metastasis in TNBC. There is a higher metastasis rate within 3 years and a lower survival rate within 5 years in TNBC. According to intervening the expressions of MMP-3 and VEGF, and inhibiting cancer cells matrix degradation and vascular formation, then cancer cells metastasis could be blocked, it may be important to reduce the 3-year recurrence rate and improve 5-year survival rate.
ObjectiveTo explore expression of epidermal growth factor receptor(EGFR) in triple-negative breast cancer(TNBC). Method The published articles about expression of EGFR in TNBC according to the inclusion and exclusion criteria from PubMed, Elsevier-Science Direct, and Web of Science databases were retrieved. The meta-analysis was performed with RevMan 5.2 software. ResultsA total of 8 articles were eligible for the meta-analysis. Among them, 1 006 patients in the TNBC group and 2 945 cases in the non-TNBC group. The result of meta-analysis showed that the positive rate of EGFR expression in the TNBC group was significantly higher than that in the non-TNBC group(OR=6.57, 95% CI 3.42-12.61, P < 0.000 01). The result of race subgroup analysis showed that the positive rate of EGFR expression of TNBC patients in Caucasian(OR=8.93, 95% CI 4.16-19.17, P < 0.000 01) or Xanthoderm(OR=2.79, 95% CI 0.99-7.89, P=0.05) was significantly increased as compared with non-TNBC patients. ConclusionThe positive rate of EGFR expression in TNBC patients is higher than that of non-TNBC patients, which might become an important marker of TNBC and an effective therapeutic target.
Objective To systematically evaluate expression of vascular endothelial growth factor (VEGF) protein in triple negative breast cancer (TNBC) and analyze its correlation between positive expression of VEGF protein and clinicopathologic features of patient with TNBC. Methods The published literatures relevant VEGF protein expression in TNBC and its relation to clinicopathologic features of patient with TNBC in China were retrieved by means of CNKI, Wanfang, VIP, China Biomedical, Chaoxing Medalink, PubMed databases, and other search tools. The literatures were independently filtered, extracted, and assessed by two reviewers according to the inclusion criteria and exclusion criteria. The meta-analysis was conducted by using RevMan 5.3 software. Results A total of 11 literatures were included and involved 1 838 patients (750 patients in the TNBC group and 1 088 patients in the non-TNBC group). The results of meta-nalysis showed that the positive expression of VEGF protein in the TNBC group was significantly higher than that in the non-TNBC group 〔OR=2.64, 95%CI (2.14, 3.26), P<0.000 01〕 , which was significantly increased in the TNBC patients with positive lymph node or stage Ⅲ–Ⅳ as compared with the negative lymph node or stage Ⅰ–Ⅱ 〔OR=0.30, 95% CI (0.14, 0.46), P=0.000 2; OR=0.43, 95% CI (0.29, 0.62), P<0.000 01〕 . However, the positive expression of VEGF protein was no associated with the age of patients with TNBC or tumor size (P>0.05). Conclusions VEGF highly expresses in TNBC and it is expected to be a new therapeutic target. Positive expression of VEGF protein is related to positive lymph node and late TNM stage, and it might be associated with prognosis of patient with TNBC.
Objective To investigate relationship between androgen receptor (AR) and clinicopathologic features of patients with triple negative breast cancer (TNBC) in Xinjiang. Methods The clinical data of Han and Uygur patients with TNBC from the First Affiliated Hospital of Xinjiang Medical University from December 2012 to December 2016 were retrospectively analyzed. And the expression of the AR and the clinicopathologic features of the patients with TNBC were extracted. The results were analyzed by SPSS 19.0. Results A total of 178 patients with TNBC were included, including 127 Han and 51 Uygur patients. The positive rate of the AR expression in the 178 patients with TNBC was 21.3% (38/178), which was significantly related to the expression of Ki-67 (χ2=15.196, P<0.001), was not related to the ethnicity (χ2=0.203, P=0.688), age (χ2=0.221, P=0.715), tumor size (χ2=0.047, P=0.855), lymph node status (χ2=0.874, P=0.354), or histological grade (χ2=0.001, P=1.000). And there were no statistically significant differences in the clinicopathologic features between the Han patients with TNBC and the Uygur patients with TNBC. Conclusion AR positive expression is related to Ki-67, but clinicopathologic features have no significant differences between Han and Uygur patients with TNBC in Xingjinag.
ObjectiveTo summarize the research progress of microRNA-200 (miR-200) family in triple-negative breast cancer (TNBC).MethodsRelevant literatures at home and abroad were systematically retrieved and read to review the research progress of miR-200 family in TNBC in recent years.ResultsThe miR-200 family played an important role in the proliferation, invasion, and metastasis of TNBC, as well as the resistance to treatment. It could also be used as potential therapeutic targets and biological predictors. Different miR-200 family members and differential expression mediated various targeting effects, which may be related to differences in signaling pathways and cellular environment.ConclusionsmiR-200 family plays a key regulatory role in the occurrence and development of TNBC, and it is expected to provide new ideas for the treatment and prognosis evaluation of TNBC. However, its mechanism of action still needs further study.
ObjectiveTo understand current research progress of microRNA (miRNA) in pathogenesis of triple-negative breast cancer (TNBC), and to provide reference for understanding pathogenesis and treatment of TNBC.MethodTheresearch progress of relationship of TNBC and miRNA was reviewed by reading relevant literatures at home and abroad in recent years.ResultsThe miRNAs were involved in a variety of biological processes, including the cell proliferation, apoptosis, autophagy, differentiation, metastasis, etc., and played an important role in the cancer initiation and metastasis. Therefore, researchers had attempted to treat and prevent the TNBC by targeting miRNAs. At present, there had been a large number of reports that the miRNAs played a key role in TNBC, which were classified as the anti-oncogene and oncogene, and was associated with metastasis and prognosis of TNBC.ConclusionmiRNA is very important in pathogenesis of TNBC. Mechanism of studying miRNA is necessary for treatment and prevention of TNBC.
ObjectiveTo summarize research progress of comprehensive treatment based on gene therapy, immunotherapy, and targeted therapy in recent years in order to improve understanding and treatment level of triple negative breast cancer (TNBC).MethodThe literatures about TNBC treatment in recent 5 years were reviewed and summarized.ResultsTNBC was more invasive than other types of breast cancer due to its lack of targeted receptors, and its recurrence and metastasis were earlier. The treatment plan was still mainly surgical treatment, supplemented by the chemotherapy and radiotherapy.ConclusionsAlthough recent studies of TNBC in surgical treatment, chemoradiotherapy, targeted therapy and other aspects have shown a good clinical application prospect, more evidences of clinical trials with large samples are still needed. With the deepening of molecular mechanism research, endocrine therapy and targeted drug therapy, including androgen-receptor-positive, have provided some new ideas for treatment of TNBC.